文摘
Busulfan, cyclophosphamide, and melphalan as a pre–hematopoietic stem cell transplantation conditioning regimen for children with acute myeloid leukemia in first complete remission offers favorable outcomes and is well tolerated. Busulfan, cyclophosphamide, and melphalan offers better chances of reducing relapse rate than total body irradiation/cyclophosphamide or busulfan, cyclophosphamide regimens The use of peripheral blood as stem cell source significantly impairs the outcome, increasing nonrelapse mortality and reducing leukemia-free and overall survival